Novo’s Next-Gen CB1 Drug Leads to Weight Loss in Phase II, but ...
WEB1 day ago · Novo Nordisk’s $1.1 billion acquisition of Inversago Pharmaceuticals last year is paying off with Phase IIa results for an oral therapy picked up in the deal. Monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse agonist, has cut weight by 15 lbs after 16 weeks of treatment, compared to just 1.5 lbs for placebo, according to ...
Novo Nordisk announces a $6 billion peptide expansion
WEBNov 15, 2023 · Novo Nordisk's project in Kalundborg, Denmark, will expand output of active pharmaceutical ingredients, notably the peptide found in two diabetes and weight loss drugs.
Novo’s obesity drug linked to ‘neuropsychiatric side effects’
WEB1 day ago · Novo obesity prospect linked to ‘mild to moderate neuropsychiatric side effects’ in phase 2. Novo Nordisk’s $1 billion bet that it had found a cannabinoid CB1 receptor blocker that could ...
EU regulator backs use of Novo's Wegovy for obesity-related …
WEB1 day ago · The European Medicines Agency backed the use of Novo Nordisk's popular drug Wegovy to help ease heart failure in people with obesity, the Danish drugmaker said on Thursday.
Novo’s Obesity Pill Yields ‘Remarkable’ 13% Weight ... - BioSpace
WEBSep 11, 2024 · The 13% weight loss seen among patients on Novo’s amycretin had already been revealed at the company’s investor day in March, but investigators provided some more detail in the full conference presentation on Tuesday. The small study featured patients with a BMI of 25 to 39 without diabetes who received either amycretin or …
R&D pipeline - Novo Nordisk
WEBBrowse our entire R&D pipeline by study phase, or select a specific therapy areas. Click on a candidate to access up-to-date trial information.
Weight loss: Amycretin pill may be more effective than semaglutide
WEBSep 12, 2024 · Share on Pinterest Novo Nordisk’s new weight loss pill, amycretin, has had promising results in an early clinical trial. Image credit: SERGEI GAPON/Getty Images. Amycretin, a new weight loss ...
Novo Nordisk Stock Dives - Investor's Business Daily
WEB1 day ago · Novo Nordisk stock tumbled 5.5%, closing at 127.51. Shares of Corbus, which is working on a similar weight-loss drug, crashed 62.3% to 19.51. Meanwhile, shares of companies working on GLP-1-based ...
Novo Nordisk’s New Obesity Pill Beats Wegovy In Early Trial
WEBSep 11, 2024 · Ozempic maker Novo Nordisk on Wednesday said data showed its hotly anticipated weight loss pill prompts greater and more rapid weight loss than its blockbuster treatment Wegovy, amid...
Obesity Drug Safe for Kids, Study Finds. Novo Nordisk Stock Rises.
WEBStory by Elsa Ohlen. • 12h. Novo Nordisk’s obesity drug may be safe and effective in people as young as six, researchers found. The drug Liraglutide was shown in a late-stage clinical trial to ...
Skip to content